Detail akcie Becton Dickinson online

Business Summary: Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Becton Dickinson and Co revenues increased 8% to $21.84B. Net income decreased 2% to $1.68B. Revenues reflect Medical segment increase of 14% to $11.46B, Interventional segment increase of 5% to $5.22B, United States segment increase of 10% to $12.79B, International segment increase of 6% to $9.05B. Dividend per share increased from $3.80 to $4.16.